PDCD1 and in situ carcinoma: In the single-arm phase 2 trial of pembrolizumab (KEYNOTE-057), a programmed cell death protein 1 (PD-1) inhibitor given in patients with high-risk BCG-unresponsive CIS showed that 41% had a complete response at three months, and 46% remained in complete response for 12 months (24).